In the ongoing effort to find drugs that safely and effectively reduce cardiovascular events, there’s a new class of stars: PCSK9 inhibitors. These drugs are antibodies directed at the PCSK9 protein, which regulates LDL receptor recycling. Blocking the protein results in increasing the effective number of receptors, which leads to
Big waistline increases risk of sudden death.
Obesity appears to be an independent risk factor for sudden cardiac death (SCD), a fatal malfunction of the heart’s electrical system, in middle-aged adults. An analysis of the Atherosclerosis Risk in Communities study published online November 19, 2014 in Heart found that SCD occurred
Statins—taken by more than 25 million Americans to combat the high cholesterol levels that can harm cardiovascular health—are highly effective when it comes to lowering the risk for cardiovascular-related events and mortality. They also are low cost, and generally safe to take. However, for some people, statins come with side
Why Some Stents May Clog With Plaque
Drug-eluting stents (DES) were developed to prevent stents from clogging with plaque (in-stent restenosis), yet the problem occurs in about 16 percent of patients. Swiss researchers recently discovered these patients tend to have aggressive plaque growth throughout all their arteries. All patients in the
Two new cholesterol-lowering drugs may do more than provide alternatives for people who have serious side effects from statins. PCSK9 inhibitors may also help bring back specific targets in cholesterol treatment guidelines.
When the American College of Cardiology and the American Heart Association developed new cholesterol guidelines with the National Heart,
Shorter Course of Radiation Beneficial for Breast Cancer Patients
Among women with breast cancer who have had a tumor surgically removed, researchers have found that a shorter course of higher-dose radiation to one area of the breast yields similar results as a longer course of radiation to the entire breast. Data
Cholesterol-lowering statins are wonder drugs for reducing low-density lipoprotein (LDL, “bad”) cholesterol and lessening cardiovascular risk. Yet, a significant number of patients cannot tolerate the medications or fail to reach target LDL levels despite being on maximum-dose statin therapy.
Enter a new class of drugs—proprotein convertase subtilisin kexin type 9 (PCSK9)